Ab&B Bio-Tech CO., LTD. JS Class H (HK:2627)
:2627
Want to see HK:2627 full AI Analyst Report?
Top Page
Ab&B Bio-Tech CO., LTD. JS Class H
(2627)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$50.00
▲(14.73% Upside)
Action:ReiteratedDate:01/17/26
The score is held down primarily by weak financial fundamentals: the company remains structurally unprofitable with ongoing cash burn and significantly higher leverage. Technicals are supportive due to strong momentum and price above key moving averages, but overbought indicators raise pullback risk. Valuation cannot be meaningfully judged due to missing P/E and dividend yield data.
Positive Factors
Strong 2024 revenue rebound and gross margin recovery
A large revenue rebound coupled with a dramatic gross margin swing indicates the business achieved meaningful pricing, mix or cost improvements. These changes improve the path to durable operating leverage and reduce the scale of revenue needed to reach sustainable profitability over the next several quarters.
Negative Factors
Persistent unprofitable operations and material cash burn
Ongoing operating losses and structural cash burn impair the company’s ability to self-fund growth or R&D. Without sustained margin expansion, the firm will remain dependent on external financing, increasing dilution risk and reducing strategic flexibility over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong 2024 revenue rebound and gross margin recovery
A large revenue rebound coupled with a dramatic gross margin swing indicates the business achieved meaningful pricing, mix or cost improvements. These changes improve the path to durable operating leverage and reduce the scale of revenue needed to reach sustainable profitability over the next several quarters.
Read all positive factors
Ab&B Bio-Tech CO., LTD. JS Class H (2627) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$11.54B
Dividend YieldN/A
Average Volume (3M)183.66K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees583
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding296,361,850
10 Day Avg. Volume177,740
30 Day Avg. Volume183,655
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)83.89
Price to Sales (P/S)47.37
P/FCF Ratio-30.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ab&B Bio-Tech CO., LTD. JS Class H Business Overview & Revenue Model
Company Description
Ab&B Bio-Tech CO., LTD. JS researchs, develops, manufactures, and sells vaccines and biological preparations that provide active immunity against diseases. The company offers various vaccines, such as human rabies vaccine, pneumococcal vaccine, zo...
Ab&B Bio-Tech CO., LTD. JS Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 71.12M | 259.61M | 52.17M |
| Gross Profit | 60.78M | 151.46M | -20.34M |
| EBITDA | -93.98M | -181.80M | -370.16M |
| Net Income | -121.52M | -258.72M | -424.74M |
Balance Sheet | |||
| Total Assets | 1.60B | 1.61B | 1.12B |
| Cash, Cash Equivalents and Short-Term Investments | 118.78M | 132.19M | 77.57M |
| Total Debt | 1.02B | 858.81M | 421.42M |
| Total Liabilities | 1.56B | 1.47B | 756.47M |
| Stockholders Equity | 36.87M | 146.59M | 363.27M |
Cash Flow | |||
| Free Cash Flow | -78.88M | -399.68M | -597.16M |
| Operating Cash Flow | -31.88M | -199.51M | -305.99M |
| Investing Cash Flow | -46.73M | -152.67M | -506.00K |
| Financing Cash Flow | 54.84M | 439.06M | 335.17M |
Ab&B Bio-Tech CO., LTD. JS Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$226.68B | 20.40 | 16.09% | 0.97% | 22.62% | 26.23% | |
63 Neutral | HK$16.60B | 8.36 | 2.86% | 5.23% | 3.74% | -40.22% | |
58 Neutral | HK$70.96B | 13.21 | 7.02% | 1.69% | 1.52% | 22.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$3.27B | -9.58 | 206.86% | ― | 92.87% | ― | |
49 Neutral | HK$11.54B | -95.71 | -142.93% | ― | ― | ― | |
44 Neutral | HK$11.94B | -42.31 | -0.02% | ― | 31.39% | 98.96% |
* Healthcare Sector Average
HK:2627
Ab&B Bio-Tech CO., LTD. JS Class H
29.32
-14.38
-32.91%
HK:2552
Hua Medicine
3.37
1.13
50.45%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
19.13
5.63
41.75%
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
4.81
0.52
12.12%
HK:3692
Hansoh Pharmaceutical Group Company Limited
37.38
13.20
54.59%
HK:6185
CanSino Biologics, Inc. Class H
29.20
-3.80
-11.52%
Ab&B Bio-Tech CO., LTD. JS Class H Corporate Events
Ab&B Bio-Tech Partners with Walvax Unit to Take Flu Vaccine Overseas
Mar 13, 2026
AbB Bio-Tech has signed a strategic cooperation agreement with Walvax Hong Kong Limited to drive overseas registration, sales and commercialization of its core trivalent subunit influenza vaccine, Huierkangxin 3. Approved in January 2026 and curre...
Ab&B Bio-Tech Wins U.S. FDA IND Nod for mRNA Mpox Vaccine, Bolstering Global Vaccine Ambitions
Mar 4, 2026
AbB Bio-Tech CO., LTD. JS, a China-based vaccine specialist, develops innovative and traditional vaccines using advanced technologies, with a strategic focus on premium products that can substitute traditional and imported vaccines in China and su...
Ab&B Bio-Tech Forecasts Strong Revenue Growth and Narrowing Loss for 2025
Feb 26, 2026
AbB Bio-Tech CO., LTD. JS has issued a profit alert indicating that its 2025 revenue is expected to surge by about 72% to 90% year on year to between RMB446 million and RMB493 million, while its net loss should narrow by roughly 24% to 39% from RM...
Ab&B Bio-Tech Added to Hang Seng Composite Index, Boosting Market Profile
Feb 16, 2026
AbB Bio-Tech CO., LTD. JS, a Chinese vaccine company specializing in innovative and premium vaccines such as quadrivalent and trivalent subunit influenza candidates and a lyophilized human rabies vaccine candidate, is positioning itself to substit...
Ab&B Bio-Tech Wins NMPA Approval for First All-Ages Trivalent Subunit Flu Vaccine in China
Jan 30, 2026
AbB Bio-Tech CO., LTD. JS, a Chinese vaccine developer specializing in premium and innovative vaccines aimed at replacing traditional and imported products in China while expanding globally, is advancing a pipeline that includes a trivalent subuni...
Ab&B Bio-Tech Announces Board and Company Secretary Resignations
Jan 12, 2026
AbB Bio-Tech CO., LTD. JS announced that non-executive director and Audit Committee member Cheng Qianwen has tendered his resignation to focus on personal pursuits, but will remain in his roles until shareholders elect a new non-executive director...
Ab&B Bio-Tech Shareholders Unanimously Back New INED and Auditor Reappointment
Dec 23, 2025
AbB Bio-Tech CO., LTD. JS reported that shareholders at its second extraordinary general meeting of 2025, held both onsite in Taizhou and online, approved all resolutions by poll with full support from the votes cast. Investors endorsed the appoin...
Ab&B Bio-Tech Outlines Board Composition and Committee Roles
Dec 23, 2025
AbB Bio-Tech CO., LTD. JS has announced the current composition of its board of directors, which includes three executive directors, three non-executive directors and three independent non-executive directors, with chairman An Youcai serving as he...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.